The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol (EMBRACE)
This treatment has been approved for sale to the public.
Information provided by:
First received: February 20, 2007
Last updated: September 16, 2011
Last verified: September 2011
The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.
|Study Type:||Expanded Access What is Expanded Access?|
Resource links provided by NLM:
Genetic and Rare Diseases Information Center resources: Paroxysmal Nocturnal Hemoglobinuria Myelodysplastic SyndromesU.S. FDA Resources
Further study details as provided by Alexion Pharmaceuticals:
Contacts and Locations